Document is current
Any future updates will be listed below
-
Authors
Njotu, Fabrice N.
Pougoue Ketchemen, Jessica
Babeker, Hanan
Henning, Nikita
Tikum, Anjong F.
Nwangele, Emmanuel
Monzer, Alissar
Hassani, Nava
Gray, Brian D.
Pak, Koon Y.
Torlakovic, Emina E.
Uppalapati, Maruti
Fonge, Humphrey https://orcid.org/0000-0001-9388-6872
-
Funding
Funding for this research was provided by:
Molecular Targeting Technologies Inc (Molecular Targeting Technologies Inc)
- License Information
-
More Information
Article History
Received: 27 July 2024
Accepted: 24 November 2024
First Online: 4 December 2024
Declarations
:
: All animal experiments were approved, supervised, and maintained following the guidelines of the University of Saskatchewan Animal Care Committee (UACC). Ethical approval reference 20220021.
: The authors have consent to publish all the data presented in the manuscript.
: Koon Y. Pak and Brian D. Gray are executives and shareholders of Molecular Targeting Technologies Inc., which owns the IP and has commercial interests in [225Ac]Ac-EBTATE.
: B. Gray and K. Pak are employees of Molecular Targeting Technologies Inc that owns the licence for EB-TATE. All other authors have declared no competing conflicts of interest.
